Statins Enhances Anti-Androgen Abiraterone Acetate Therapeutic Efficacy on Castration-Resistant Prostate Cancer Cells | Chapter 10 | New Horizons in Medicine and Medical Research Vol. 2

 Treatment options for castration-resistant (CR) prostate cancer (PCa) are limited. Because a significant subset of CR PCa tumours can produce androgens for intracrine androgen receptor (AR) activation, blocking androgen biosynthesis may be a viable therapy strategy for these individuals.

Simvastatin, atorvastatin, and ketoconazole were found to directly suppress growth, migration, and colony formation of androgen-independent LNCaP C-81 cells that exhibit de novo androgen production, with simvastatin being the most effective. Statins, in particular, increased growth suppression in combination with anti-androgen abiraterone acetate actions on CR PCa cells.

To improve anti-androgen therapy for CR PCa, statins can be combined with abiraterone acetate.

Author(S) Details

Dannah R. Miller
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.

Matthew A. Ingersoll
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.

Yu-wei Chou
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.

Ming-Fong Lin
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA and Section of Urological Surgery, School of Medicine, University of Nebraska Medical Center, Omaha, NE, USA and Eppley Institute for Cancer Research, University of Nebraska, Medical Center, Omaha, NE, USA and College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.

View Book:- https://stm.bookpi.org/NHMMR-V2/article/view/6130